Safety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control Study

Table 1

Demographics.

Characteristics	Case group ()	Control group ()	value
Age, years	27 17–39]	28 17–40]	0.71
Parity,	1 0–4]	1 0–4]	0.87
Ethnicity
Caucasian	5 (8%)	22 (34%)	0.00
African descent	38 (59%)	15 (23%)
Other	11 (17%)	16 (25%)
Unknown	10 (16%)	11 (17%)
Education level
Lower education	13 (20%)	10 (16%)	0.18
Middle education	21 (33%)	12 (19%)
Higher education	7 (11%)	12 (19%)
Unknown	23 (36%)	29 (46%)
Comorbidities^†
Overall	13 (20%)	12 (19%)	0.12
Preexisting hypertension	1 (2%)	2 (3%)
Preexisting diabetes	1 (2%)	2 (3%)
Renal/liver transplant	1 (2%)	0
Renal malignancy in the past	1 (2%)	1 (2%)
Irritable bowel syndrome	0	1 (2%)
Uterus myomatosus	2 (3%)	1 (2%)
Primary hyperoxaluria type 1	1 (2%)	0
Asthma	1 (2%)	1 (2%)
Hypothyroidism	2 (3%)	1 (2%)
Sickle cell anemia	2 (3%)	1 (2%)
Rheumatoid arthritis	1 (2%)	0
Ehlers-Danlos type III	0	1 (2%)
Alpha thalassemia	0	1 (2%)
HIV infection	1 (2%)	1 (2%)
IL-12 receptor deficiency	0	1 (2%)
Unknown	4	0
Familial diseases
None	14 (22%)	36 (56%)	0.00
Hypertension	14 (22%)	8 (13%)
Diabetes	6 (9%)	3 (5%)
Hypertension and diabetes	18 (28%)	13 (20%)
Unknown	12 (19%)	4 (6%)
Number of fetuses
Singleton pregnancy	59 (92%)	59 (92%)	1.00
Twin pregnancy	5 (8%)	5 (8%)

Data shown as median [range] or (%); ^†patients could have more than one comorbidity.